|
Recruitment at Royal Melbourne Hospital Commences
|
29 June 2023 at 8:45am
|
|
$1.75M Manufacturing Grant Payment Received
|
13 June 2023 at 9:30am
|
|
Leadership Transition
|
31 May 2023 at 9:25am
|
|
Stage 2 of Clinical Trial Activated
|
29 May 2023 at 8:40am
|
|
Change of Director's Interest Notice
|
5 May 2023 at 1:45pm
|
|
Cleansing Notice
|
5 May 2023 at 1:45pm
|
|
Application for quotation of securities - EMV
|
5 May 2023 at 1:40pm
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
27 April 2023 at 8:25am
|
|
Notification regarding unquoted securities - EMV
|
24 April 2023 at 4:05pm
|
|
Product Development Milestones & Grant Funding Achieved
|
17 April 2023 at 8:45am
|
|
Cleansing Notice
|
3 April 2023 at 8:45am
|
|
Application for quotation of securities - EMV
|
3 April 2023 at 8:45am
|
|
Clinical Advisory Board Appointment
|
14 March 2023 at 8:35am
|
|
CEO Half-Year Update
|
28 February 2023 at 8:25am
|
|
Half Yearly Report and Accounts
|
28 February 2023 at 8:15am
|
|
Clinical Trial Stage 1 Enrolment Completed
|
21 February 2023 at 8:25am
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
31 January 2023 at 8:10am
|
|
Trial Progressing on Target and ASA Milestone Achieved
|
25 January 2023 at 9:35am
|
|
Change of Director's Interest Notice X 6
|
1 December 2022 at 5:15pm
|
|
Notification regarding unquoted securities - EMV
|
1 December 2022 at 5:15pm
|
|
$8.8m In Non-Dilutive Funding To Be Received This Quarter
|
1 December 2022 at 8:40am
|
|
EMVision Commences Clinical Trial
|
30 November 2022 at 8:40am
|
|
Results of Annual General Meeting
|
16 November 2022 at 12:10pm
|
|
AGM Chairman Address and Presentation
|
16 November 2022 at 10:35am
|
|
Portable Brain Scanner Delivered to First Clinical Site
|
14 November 2022 at 8:45am
|
|
EMVision Backed By NSW Medical Devices Fund With $2.5m Grant
|
11 November 2022 at 8:40am
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
31 October 2022 at 9:40am
|
|
$5m Modern Manufacturing Initiative Funding Agreement Signed
|
25 October 2022 at 8:35am
|
|
Notice of Annual General Meeting/Proxy Form
|
14 October 2022 at 4:55pm
|
|
Ethics Approval Received For Multi-Centre Clinical Trial
|
4 October 2022 at 8:25am
|
|
Cleansing Notice
|
16 September 2022 at 11:55am
|
|
Application for quotation of securities - EMV
|
16 September 2022 at 11:45am
|
|
Notification regarding unquoted securities - EMV
|
16 September 2022 at 11:35am
|
|
Employee Incentive Plan Issue
|
16 September 2022 at 11:30am
|
|
Date of AGM and Closing Date for Director Nominations
|
16 September 2022 at 8:45am
|
|
Investor Presentation - E&P Healthcare Conference
|
6 September 2022 at 9:10am
|
|
Appendix 4G & Corporate Governance Statement
|
30 August 2022 at 9:10am
|
|
Appendix 4E & Annual Report to 30 June 2022
|
30 August 2022 at 9:10am
|
|
$5m Modern Manufacturing Initiative Grant Proceeding
|
29 August 2022 at 9:30am
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
28 July 2022 at 8:35am
|
|
Centres of Excellence Confirmed as First Two Clinical Sites
|
12 July 2022 at 8:40am
|
|
Cleansing Notice
|
29 June 2022 at 5:50pm
|
|
Application for quotation of securities - EMV
|
29 June 2022 at 5:40pm
|
|
EMVision Achieves First Responder Milestone
|
27 June 2022 at 8:40am
|
|
EMVision Awarded $5m Non-Dilutive Funding via MMI Grant
|
18 May 2022 at 10:00am
|
|
Trading Halt
|
16 May 2022 at 12:25pm
|
|
Pause in Trading
|
16 May 2022 at 12:05pm
|
|
Cleansing Notice
|
13 May 2022 at 5:30pm
|
|
Application for quotation of securities - EMV
|
13 May 2022 at 5:25pm
|
|
EMVision Secures Strategic Agreement With Keysight
|
4 May 2022 at 10:30am
|
